Brokerages forecast that Perrigo Company (NYSE:PRGO) will report $1.11 earnings per share for the current fiscal quarter, according to Zacks. Twelve analysts have provided estimates for Perrigo’s earnings, with estimates ranging from $1.02 to $1.18. Perrigo posted earnings per share of $1.65 in the same quarter last year, which would suggest a negative year over year growth rate of 32.7%. The business is expected to report its next earnings report on Thursday, November 9th.

According to Zacks, analysts expect that Perrigo will report full-year earnings of $4.52 per share for the current year, with EPS estimates ranging from $4.30 to $4.64. For the next year, analysts expect that the company will report earnings of $5.09 per share, with EPS estimates ranging from $4.79 to $5.38. Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Perrigo.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Thursday, August 10th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.28. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.18 billion. Perrigo had a positive return on equity of 11.55% and a negative net margin of 51.04%. The firm’s revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.93 EPS.

PRGO has been the topic of a number of analyst reports. Wells Fargo & Company reiterated a “market perform” rating and set a $77.00 price objective on shares of Perrigo in a research report on Tuesday, August 15th. Stifel Nicolaus reiterated a “hold” rating on shares of Perrigo in a research report on Friday, August 11th. Canaccord Genuity set a $80.00 price objective on Perrigo and gave the stock a “buy” rating in a research report on Wednesday, May 31st. Royal Bank Of Canada downgraded Perrigo from a “sector perform” rating to an “underperform” rating and reduced their price objective for the stock from $66.00 to $60.00 in a research report on Monday, June 5th. Finally, Cantor Fitzgerald set a $85.00 price objective on Perrigo and gave the stock a “buy” rating in a research report on Monday, July 24th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $87.00.

Shares of Perrigo (NYSE PRGO) traded up 4.93% on Thursday, hitting $82.19. The company had a trading volume of 3,830,512 shares. Perrigo has a 52 week low of $63.68 and a 52 week high of $99.14. The company’s market capitalization is $11.72 billion. The stock’s 50-day moving average is $75.43 and its 200 day moving average is $72.98.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Friday, August 25th will be given a $0.16 dividend. The ex-dividend date is Wednesday, August 23rd. This represents a $0.64 dividend on an annualized basis and a yield of 0.78%. Perrigo’s dividend payout ratio is currently -3.51%.

In other news, EVP Thomas Farrington sold 865 shares of Perrigo stock in a transaction on Friday, August 18th. The stock was sold at an average price of $78.40, for a total value of $67,816.00. Following the completion of the sale, the executive vice president now directly owns 2,870 shares of the company’s stock, valued at $225,008. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Sharon Kochan sold 1,500 shares of Perrigo stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $79.03, for a total value of $118,545.00. Following the completion of the sale, the executive vice president now directly owns 10,349 shares of the company’s stock, valued at $817,881.47. The disclosure for this sale can be found here. Insiders sold 2,981 shares of company stock worth $233,731 in the last 90 days. Company insiders own 6.90% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Korea Investment CORP grew its stake in shares of Perrigo by 142.0% in the second quarter. Korea Investment CORP now owns 1,331 shares of the company’s stock valued at $101,000 after buying an additional 781 shares in the last quarter. Commonwealth Bank of Australia grew its stake in shares of Perrigo by 13.8% in the second quarter. Commonwealth Bank of Australia now owns 1,455 shares of the company’s stock valued at $108,000 after buying an additional 176 shares in the last quarter. Johnson Financial Group Inc. grew its stake in shares of Perrigo by 15.6% in the first quarter. Johnson Financial Group Inc. now owns 1,775 shares of the company’s stock valued at $118,000 after buying an additional 240 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of Perrigo by 1,046.2% in the second quarter. Bessemer Group Inc. now owns 2,235 shares of the company’s stock valued at $169,000 after buying an additional 2,040 shares in the last quarter. Finally, Global X Management Co. LLC grew its stake in shares of Perrigo by 56.4% in the first quarter. Global X Management Co. LLC now owns 2,370 shares of the company’s stock valued at $157,000 after buying an additional 855 shares in the last quarter. 80.36% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/07/1-11-earnings-per-share-expected-for-perrigo-company-prgo-this-quarter.html.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.

Get a free copy of the Zacks research report on Perrigo (PRGO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.